Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal …

V Piñol, A Castells, M Andreu, S Castellví-Bel… - Jama, 2005 - jamanetwork.com
ContextThe selection of individuals for hereditary nonpolyposis colorectal cancer (HNPCC)
genetic testing is challenging. Recently, the National Cancer Institute outlined a new set of …

[HTML][HTML] Serrated polyposis syndrome: molecular, pathological and clinical aspects

C Guarinos, C Sánchez-Fortún… - World journal of …, 2012 - ncbi.nlm.nih.gov
Hyperplastic polyps have traditionally been considered not to have malignant potential. New
pathological classification of serrated polyps and recent discoveries about the serrated …

Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

R Jover, P Zapater, A Castells, X Llor, M Andreu… - Gut, 2006 - gut.bmj.com
Aim: Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU)
adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer …

Risk of cancer in cases of suspected lynch syndrome without germline mutation

M Rodríguez–Soler, L Pérez–Carbonell, C Guarinos… - Gastroenterology, 2013 - Elsevier
BACKGROUND & AIMS: Colorectal cancers (CRCs) with microsatellite instability (MSI) and
a mismatch repair (MMR) immunohistochemical deficit without hypermethylation of the …

Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with …

L Pérez-Carbonell, C Ruiz-Ponte, C Guarinos… - Gut, 2012 - gut.bmj.com
Background The selection of patients for genetic testing to rule out Lynch syndrome is
currently based on fulfilment of at least one of the revised Bethesda criteria followed by …

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status

R Jover, P Zapater, A Castells, X Llor, M Andreu… - European journal of …, 2009 - Elsevier
AIMS: The aim of this study is to evaluate if mismatch repair (MMR) defective colorectal
cancer has a different response to adjuvant 5-fluorouracil (5-FU) chemotherapy in a cohort …

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer

R Jover, TP Nguyen, L Pérez–Carbonell, P Zapater… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: 5-Fluorouracil (5-FU)–based adjuvant chemotherapy does not
increase survival times of patients with colorectal tumors with microsatellite instability. We …

New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis

L Valle, E Hernández-Illán, F Bellido… - Human molecular …, 2014 - academic.oup.com
Germline mutations in DNA polymerase ɛ (POLE) and δ (POLD1) have been recently
identified in families with multiple colorectal adenomas and colorectal cancer (CRC). All …

Performance of different microsatellite marker panels for detection of mismatch repair–deficient colorectal tumors

RM Xicola, X Llor, E Pons, A Castells… - Journal of the …, 2007 - academic.oup.com
Background Colorectal tumors caused by failure of the DNA mismatch repair system
commonly show microsatellite instability. Our goals were to compare the performance of two …

Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology

S Benlloch, A Payá, C Alenda, X Bessa… - The Journal of Molecular …, 2006 - Elsevier
Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in
colorectal carcinoma (CRC) suggests a sporadic origin of the disease, providing an …